Published in Nephrol Dial Transplant on April 12, 2013
Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol (2013) 1.06
The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant (2013) 0.93
The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant (2013) 0.90
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med (2014) 0.88
Parathyroid hormone may be an early predictor of low serum hemoglobin concentration in patients with not advanced stages of chronic kidney disease. J Nephrol (2014) 0.85
Maximal standard dose of parenteral iron for hemodialysis patients: an MRI-based decision tree learning analysis. PLoS One (2014) 0.85
Reassessment of Iron Biomarkers for Prediction of Dialysis Iron Overload: An MRI Study. PLoS One (2015) 0.84
International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol (2015) 0.81
Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. Biologics (2014) 0.80
The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients. Int J Nephrol Renovasc Dis (2016) 0.79
Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J (2016) 0.77
Is Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure? Int J Mol Sci (2015) 0.76
Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study. BMC Nephrol (2017) 0.75
Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials. Adv Ther (2016) 0.75
Successful creation of an anemia management algorithm for hemodialysis patients. Int J Nephrol Renovasc Dis (2015) 0.75
Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study). Int Urol Nephrol (2015) 0.75
Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM study. Adv Ther (2014) 0.75
Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study. Nephrol Dial Transplant (2016) 0.75
Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients. PLoS One (2016) 0.75
Association of anemia and mineral and bone disorder with health-related quality of life in Asian pre-dialysis patients. Health Qual Life Outcomes (2016) 0.75
Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis. PLoS One (2015) 0.75
Assessing the Association between Serum Ferritin, Transferrin Saturation, and C-Reactive Protein in Northern Territory Indigenous Australian Patients with High Serum Ferritin on Maintenance Haemodialysis. Int J Nephrol (2017) 0.75
Serum hepcidin predicts uremic accelerated atherosclerosis in chronic hemodialysis patients with diabetic nephropathy. Chin Med J (Engl) (2015) 0.75
Role of Hypertension and Anaemia in Left Ventricular Remodelling in Patient with Renal Allograft in the First Post-transplant Year. Mater Sociomed (2015) 0.75
Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients? J Nephrol (2017) 0.75
Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol (2017) 0.75
Safety of intravenous iron in hemodialysis patients. Hemodial Int (2017) 0.75
Acute renal failure. Lancet (2005) 5.60
Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant (2004) 4.27
Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Kidney Int (2010) 3.53
EBPG on Vascular Access. Nephrol Dial Transplant (2007) 3.26
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol (2014) 3.06
Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol (2007) 3.06
Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med (2013) 2.96
The burden of kidney disease: improving global outcomes. Kidney Int (2004) 2.94
Management of crush-related injuries after disasters. N Engl J Med (2006) 2.90
Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol (2009) 2.89
Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol (2008) 2.76
EBPG guideline on nutrition. Nephrol Dial Transplant (2007) 2.68
Acute kidney injury: an increasing global concern. Lancet (2013) 2.61
Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant (2012) 2.59
Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol (2004) 2.47
Acute kidney injury. Lancet (2008) 2.44
Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Nephrol Dial Transplant (2008) 2.42
Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant (2008) 2.41
The importance of standardization of creatinine in the implementation of guidelines and recommendations for CKD: implications for CKD management programmes. Nephrol Dial Transplant (2005) 2.38
Recommendation for the management of crush victims in mass disasters. Nephrol Dial Transplant (2012) 2.27
Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant (2008) 2.24
Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol (2007) 2.19
Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro peritoneal dialysis. Nephrol Dial Transplant (2006) 2.17
Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis (2003) 2.17
Noninvasive assessment of local pulse pressure: importance of brachial-to-radial pressure amplification. Hypertension (2005) 2.15
Management of atrial fibrillation in chronic kidney disease: double trouble. Am Heart J (2013) 2.14
Electrocardiographic P-wave characteristics in patients with end-stage renal disease: P-index and interatrial block. Int Urol Nephrol (2012) 2.12
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant (2014) 2.10
Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr (2007) 2.07
Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant (2009) 2.06
Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant (2002) 2.05
The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol (2006) 2.01
[In Process Citation]. Lakartidningen (2015) 2.01
A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant (2012) 1.94
Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int (2009) 1.93
Chronic kidney disease in adults--UK guidelines for identification, management and referral. Nephrol Dial Transplant (2006) 1.91
EBPG guideline on dialysis strategies. Nephrol Dial Transplant (2007) 1.90
Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol (2012) 1.90
Association of dialysate bicarbonate concentration with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2013) 1.90
Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory Board. Nephrol Dial Transplant (2010) 1.90
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis (2006) 1.88
Global differences in dialysis modality mix: the role of patient characteristics, macroeconomics and renal service indicators. Nephrol Dial Transplant (2013) 1.88
The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int (2004) 1.83
Vascular calcification in chronic kidney disease. Am J Kidney Dis (2004) 1.81
Serum albumin as predictor of nutritional status in patients with ESRD. Clin J Am Soc Nephrol (2012) 1.80
Mini-peritoneal equilibration test: A simple and fast method to assess free water and small solute transport across the peritoneal membrane. Kidney Int (2005) 1.80
Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes. Am J Kidney Dis (2007) 1.77
Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant (2006) 1.74
Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int (2004) 1.72
Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol (2010) 1.70
A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl (2003) 1.69
Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. Kidney Int (2013) 1.68
The personal dialysis capacity test is superior to the peritoneal equilibration test to discriminate inflammation as the cause of fast transport status in peritoneal dialysis patients. Clin J Am Soc Nephrol (2005) 1.67
The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant (2006) 1.65
Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.65
Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrol Dial Transplant (2010) 1.65
EBPG guideline on haemodynamic instability. Nephrol Dial Transplant (2007) 1.65
Why less success of the peritoneal dialysis programmes in Europe? Nephrol Dial Transplant (2008) 1.65
Predicting mortality in haemodialysis patients: a comparison between lung ultrasonography, bioimpedance data and echocardiography parameters. Nephrol Dial Transplant (2013) 1.62
Clinical findings in the renal victims of a catastrophic disaster: the Marmara earthquake. Nephrol Dial Transplant (2002) 1.60
Coronary artery calcification measured with electron-beam computerized tomography correlates poorly with coronary artery angiography in dialysis patients. Am J Kidney Dis (2004) 1.60
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study. Am J Kidney Dis (2004) 1.58
Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am J Kidney Dis (2005) 1.57
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab (2014) 1.57
Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. Am J Kidney Dis (2009) 1.54
P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant (2006) 1.53
Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant (2006) 1.53
New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant (2011) 1.52
Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. Hypertension (2005) 1.52
Severity of sepsis-induced acute kidney injury in a novel mouse model is age dependent. Crit Care Med (2012) 1.52
Relationship between fluid status and its management on acute renal failure (ARF) in intensive care unit (ICU) patients with sepsis: a prospective analysis. J Nephrol (2005) 1.51
Catheter-related blood stream infections (CRBSI): a European view. Nephrol Dial Transplant (2010) 1.50
Global variation in renal replacement therapy for end-stage renal disease. Nephrol Dial Transplant (2011) 1.50
Acute central hemodynamic effects of a volume exchange in peritoneal dialysis. Perit Dial Int (2008) 1.49
Defining acute renal failure: RIFLE and beyond. Clin J Am Soc Nephrol (2006) 1.49
Therapeutic interventions favorably influencing delayed and slow graft function in kidney transplantation: mission impossible? Transplantation (2008) 1.49
The effect of magnesium supplements on early post-transplantation glucose metabolism: a randomized controlled trial. Transpl Int (2014) 1.48